119 related articles for article (PubMed ID: 10325518)
1. Statistical considerations of chemoprevention clinical trials in prostate cancer.
Sylvester R; Collette L
Eur Urol; 1999; 35(5-6):519-22. PubMed ID: 10325518
[TBL] [Abstract][Full Text] [Related]
2. Practical aspects of clinical trials on chemoprevention of prostate cancer.
van der Meijden AP
Eur Urol; 1999; 35(5-6):515-8. PubMed ID: 10325517
[TBL] [Abstract][Full Text] [Related]
3. Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.
Packianathan S; Mehta RG; Mehta RR; Hall WH; Boerner PS; Beckett LA; Vijayakumar S
Cancer J; 2004; 10(6):357-67. PubMed ID: 15701267
[TBL] [Abstract][Full Text] [Related]
4. Design considerations for efficient prostate cancer chemoprevention trials.
Lee JJ; Lieberman R; Sloan JA; Piantadosi S; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):205-12. PubMed ID: 11295629
[TBL] [Abstract][Full Text] [Related]
5. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
6. A review of phase III clinical trials of prostate cancer chemoprevention.
Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
[TBL] [Abstract][Full Text] [Related]
7. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials.
Tangen CM; Goodman PJ; Crowley JJ; Thompson IM
J Urol; 2004 Feb; 171(2 Pt 2):S64-7. PubMed ID: 14713757
[TBL] [Abstract][Full Text] [Related]
8. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.
Unger JM; Barlow WE; Tangen CM; Ramsey SD; Thompson IM; Klein EA; LeBlanc M; Blanke CD; Goodman PJ; Minasian LM; Nghiem VT; Hershman DL
Cancer Epidemiol; 2018 Aug; 55():117-122. PubMed ID: 29936140
[TBL] [Abstract][Full Text] [Related]
9. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer.
Bosland MC
Eur Urol; 1999; 35(5-6):459-63. PubMed ID: 10325505
[TBL] [Abstract][Full Text] [Related]
10. Design and analysis of prostate cancer trials.
Sylvester R
Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
[TBL] [Abstract][Full Text] [Related]
11. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
12. The prostate cancer prevention trial: design, biases and interpretation of study results.
Goodman PJ; Thompson IM; Tangen CM; Crowley JJ; Ford LG; Coltman CA
J Urol; 2006 Jun; 175(6):2234-42. PubMed ID: 16697846
[TBL] [Abstract][Full Text] [Related]
13. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
14. The Prostate Cancer Prevention Trial and the future of chemoprevention.
Thompson IM; Tangen CM; Lucia MS
BJU Int; 2008 Apr; 101(8):933-4. PubMed ID: 18353157
[No Abstract] [Full Text] [Related]
15. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer chemoprevention: current status and future prospects.
Gupta S
Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention strategies for prostate cancer.
Bosland MC; McCormick DL; Melamed J; Walden PD; Zeleniuch-Jacquotte A; Lumey LH
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S18-27. PubMed ID: 12570331
[TBL] [Abstract][Full Text] [Related]
18. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
Li B; Grambsch P
Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
[TBL] [Abstract][Full Text] [Related]
19. The Prostate Cancer Prevention Trial: design, status, and promise.
Thompson IM; Tangen C; Goodman P
World J Urol; 2003 May; 21(1):28-30. PubMed ID: 12756491
[TBL] [Abstract][Full Text] [Related]
20. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.
Kumar N; Crocker T; Smith T; Pow-Sang J; Spiess PE; Egan K; Quinn G; Schell M; Sebti S; Kazi A; Chuang T; Salup R; Helal M; Zagaja G; Trabulsi E; McLarty J; Fazili T; Williams CR; Schreiber F; Slaton J; Anderson JK
Contemp Clin Trials; 2012 Mar; 33(2):279-85. PubMed ID: 22101219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
